Tobacco smoking (accelerated aging)

Tobacco smoking is one of the strongest known modifiable accelerators of biological aging, acting through at least three converging mechanisms: epigenetic reprogramming via altered DNA methylation patterns, oxidative-stress-driven telomere attrition, and chronic low-grade inflammation promoting vascular and tissue senescence. In respiratory tissues, Wu et al. (2019, Clinical Epigenetics) found an average epigenetic age excess of 4.9 years in airway epithelium and 4.3 years in lung parenchyma among smokers; airway acceleration was partly reversible after cessation, whereas lung parenchyma acceleration persisted. Gao et al. (2016, Oncotarget) identified 66 of 150 smoking-associated CpG methylation sites that also overlapped with age-associated CpGs — though that study found no significant association between self-reported smoking status per se and overall epigenetic age acceleration, pointing to complexity in the methylation-aging relationship. The GrimAge clock (Lu et al. 2019) — which incorporates a DNAm-based surrogate for smoking pack-years and predicts time-to-death with Cox P = 2×10⁻⁷⁵ across large cohorts — illustrates how tightly smoking biology is woven into mortality risk. A meta-analysis of 84 telomere studies (Astuti et al. 2017) confirmed shorter leukocyte telomere length in current smokers versus never-smokers, consistent with increased oxidative DNA damage. Evidence is predominantly observational; causal inference rests on biological plausibility and dose-response patterns, while randomised cessation trials measuring epigenetic endpoints remain limited in size.